• Shinju Obara, Tsuyoshi Imaizumi, Takahiro Hakozaki, Atsuyuki Hosono, Yuzo Iseki, Norie Sanbe, and Masahiro Murakawa.
• Surgical Operation Department, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan. obashin99@gmail.com.
• J Anesth. 2018 Feb 1; 32 (1): 33-40.

PurposeLittle information is available on the predictive ability of previously published pharmacokinetic models of dexmedetomidine in patients under spinal anesthesia. We evaluated nine published pharmacokinetic models that were constructed in different study settings.MethodsSixteen patients received dexmedetomidine infusions after spinal anesthesia according to the manufacturer's recommended regimen (6 µg/kg/h over 10 min followed by 0.2-0.7 µg/kg/h) or target-controlled infusion (initial target of 1.5 ng/ml using the Dyck model). Dexmedetomidine concentrations were measured and median performance error (MDPE), median absolute performance error (MDAPE), and wobble were calculated.ResultsA total of 84 blood samples were analyzed. The pharmacokinetic model reported by Hannivoort et al. had the greatest ability to predict dexmedetomidine concentrations (MDPE 5.6%, MDAPE 18.1%, and wobble 6.2%).ConclusionsHannivoort et al.'s pharmacokinetic model, constructed with a dataset obtained from healthy volunteers, can predict dexmedetomidine concentrations best during continuous infusion under spinal anesthesia.

17 keywords...

hide…